Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 6/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2239951 | 1.00 | ATM (0.37) | ATMNR1H3HCRTR2MAOBBACE1 | |
| SCHEMBL3337661 | 0.92 | ATM (0.39) | ATMNR1H3HCRTR2MAOBBACE1 | |
| SCHEMBL2306925 | 0.92 | ATM (0.39) | ATMNR1H3HCRTR2MAOBBACE1 | |
| SCHEMBL176720 | 0.92 | ATM (0.38) | ATMNR1H3HCRTR2MAOBBACE1 | |
| SCHEMBL2240547 | 0.92 | ATM (0.38) | ATMNR1H3HCRTR2MAOBBACE1 | |
| SCHEMBL177178 | 0.92 | ATM (0.40) | ATMNR1H3HCRTR2MAOBMEN1 | |
| SCHEMBL11897328 | 0.91 | ATM (0.37) | ATMNR1H3HCRTR2MAOBBACE1 | |
| SCHEMBL11897329 | 0.91 | ATM (0.37) | ATMNR1H3HCRTR2MAOBBACE1 | |
| SCHEMBL2239875 | 0.90 | MCL1 (0.37) | ATMNR1H3HCRTR2 | |
| SCHEMBL2239879 | 0.90 | MCL1 (0.37) | ATMNR1H3HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120225909-A1 | INDAZOLE ANALOG | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-09-06 | — | — | US | disclosed |
| EP-2484668-A1 | INDAZOLE ANALOGUE | Asahi Kasei Pharma Corporation (JP) | 2012-08-08 | — | — | EP | disclosed |
| US-8008506-B2 | Indazole compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-08-30 | — | — | US | disclosed |
| US-20100160256-A1 | INDAZOLE COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225909-A1 | INDAZOLE ANALOG | ADRB3, ADRB1, ADRB2 | ATM 1559/4885NR1H3 83/4885HCRTR2 237/4885 |
| US-20100160256-A1 | INDAZOLE COMPOUNDS | GPR119, ADRB1, ADRA1A | ATM 2017/4885NR1H3 76/4885HCRTR2 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.